ClinicalTrials.gg
CompletedNCT05110846Updated Feb 5, 2026

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

A Phase 2 interventional study of Placebo and CT-868 in Obesity, Overweight and Type 2 Diabetes Mellitus, sponsored by Carmot Therapeutics, Inc.. Completed at 5 sites in Mexico. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.

Enrollment
14th of 21
103 · median 300
Started
2022
the only one that year
Phase 2
7 of 21
1 open now
Registered
3rd of 21
by date

Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 14th largest by enrollment, is the only one that started in 2022, is one of 7 in phase 2, and was the 3rd registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by Hoffmann-La Roche, or all of them as a file.
02

Study summary

A study to assess the effect of CT-868 in lowering glycated hemoglobin A1c (HbA1c) in overweight and obese participants with inadequately controlled Type 2 diabetes mellitus (T2DM).

03

Conditions studied

  • Obesity
  • Overweight
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or Females with T2DM
  • of ≥27 kg/m2, inclusive
  • 18-75 years old, inclusive
  • Stable body weight for 3 months

Exclusion criteria

Exclusion Criteria:

  • Significant medical history
  • Uncontrolled diabetes
  • History of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants in the placebo arm received volume- and regimen-matched placebo.

    Drug: Placebo

  • Experimental
    CT-868 1.75 mg

    Participants in the CT-868 1.75 mg arm received 1.0 mg/day for 2 weeks followed by 1.75 mg/day for the remaining treatment period.

    Drug: CT-868

  • Experimental
    CT-868 4.0 mg

    Participants in the CT-868 4.0 mg arm escalated through 1.0 mg/day for 2 weeks, 1.75 mg/day for 2 weeks, 2.5 mg/day for 4 weeks, 3.25 mg/day for 4 weeks, to 4.0 mg/day for the remaining 14 weeks.

    Drug: CT-868

Interventions

  • DrugPlacebo

    Participants self-injected once-daily subcutaneous volume- and regimen-matched placebo for 26 weeks.

  • DrugCT-868

    Participants self-injected once-daily subcutaneous CT-868 for 26 weeks according to the randomized dose and regimen.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Glycated Hemoglobin A1c (HbA1c) at Week 26

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Change from Baseline in HbA1c at Week 12

    Time frame: Baseline and Week 12

  2. Percentage of Participants Achieving HbA1c <5.7% at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  3. Percentage of Participants Achieving HbA1c ≤6.5% at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  4. Percentage of Participants Achieving HbA1c <7.0% at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  5. Percent Change from Baseline in Body Weight at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  6. Absolute (kg) Change from Baseline in Body Weight at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  7. Percentage of Participants with ≥5% Body Weight Loss from Baseline at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  8. Percentage of Participants with ≥10% Body Weight Loss from Baseline at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  9. Percentage of Participants with ≥15% Body Weight Loss from Baseline at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  10. Percentage of Participants with ≥20% Body Weight Loss from Baseline at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  11. Change from Baseline in Fasting Plasma Glucose at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  12. Change from Baseline in Fasting Insulin at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  13. Change from Baseline in Waist Circumference at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  14. Change from Baseline in Hip Circumference at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  15. Change from Baseline in Waist-to-Hip Ratio at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  16. Change from Baseline in Waist-to-Height Ratio at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  17. Change from Baseline in Body Mass Index (BMI) at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  18. Change from Baseline in Total Cholesterol at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  19. Change from Baseline in Triglycerides at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  20. Change from Baseline in Low Density Lipoprotein (LDL) Cholesterol at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  21. Change from Baseline in High Density Lipoprotein (HDL) Cholesterol at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  22. Change from Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  23. Change from Baseline in Apolipoprotein B at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  24. Change from Baseline in Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  25. Change from Baseline in Quantitative Insulin Sensitivity Check Index (QUICKI) at Weeks 12 and 26

    Time frame: Baseline and Weeks 12 and 26

  26. Percentage of Participants with at Least One Treatment-Emergent Adverse Event

    Time frame: From first dose of study drug until 4 weeks after the last dose of study drug (30 weeks)

  27. Percentage of Participants with at Least One Hypoglycemic Event

    Time frame: From first dose of study drug until 4 weeks after the last dose of study drug (30 weeks)

  28. Percentage of Participants Testing Positive for Anti-Drug Antibodies to CT-868 at Baseline and Anytime Post-Baseline

    Time frame: Baseline and Post-Baseline (up to 30 weeks)

07

Study locations

5 sites
  • Carmot Clinical Center MX04
    Guadalajara, Jalisco, Mexico
  • Carmot Clinical Center MX01
    Monterrey, Nuevo León, Mexico
  • Carmot Clinical Center MX02
    Monterrey, Nuevo León, Mexico
  • Carmot Clinical Center MX05
    Mérida, Yucatán, Mexico
  • Carmot Clinical Center MX03
    Mexico City, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Feb 2023, 12 months.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 12 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2021
First posted
Nov 8, 2021
StartActual
Feb 22, 2022
Primary completionActual
Feb 28, 2023
CompletionActual
Feb 28, 2023
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05110846
Collaborators
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Feb 22, 2022
Primary completion
Feb 28, 2023
Completion
Feb 28, 2023
Last update
Feb 5, 2026

Study contacts

Clinical Trials
study director · Carmot Therapeutics, Inc., a Member of the Roche Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CT-868

Start the discussion